Optimizing coordinated reset deep brain stimulation for Parkinson's disease

优化帕金森病的协调重置深部脑刺激

• 批准号: 10413216
• 负责人: Jing Wang
• 金额: $ 62.56万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-30 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10413216
• 关键词: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute; Advanced Development; Adverse effects; Affect; Animals; Area; Basal Ganglia; Behavioral; Biological Markers; Brain; Clinical; Clinical Research; Consumption; Data; Deep Brain Stimulation; Development; Dorsal; Effectiveness; Evaluation; Experimental Designs; Frequencies; Future; Globus Pallidus; Goals; Healthcare Systems; Hour; Implant; Incidence; Lead; Life; MPTP non-human primate; Measures; Modeling; Motor; Movement; Neurodegenerative Disorders; Neurons; Nodal; Operative Surgical Procedures; Outcome; Parkinson Disease; Parkinsonian Disorders; Patient Care; Patients; Pattern; Persons; Prefrontal Cortex; Probability; Quality of life; Research; Rest; Site; Structure; Structure of subthalamic nucleus; Testing; Therapeutic; Therapeutic Effect; Time; Translations; Utah; Work; base; density; effective therapy; human subject; improved; motor disorder; motor function improvement; motor symptom; neurotransmission; nonhuman primate; novel; novel strategies; preclinical study; relating to nervous system; side effect; specific biomarkers; therapeutically effective

PROJECT SUMMARY/ABSTRACT Parkinson’s disease (PD) is a neurodegenerative disorder affecting 6-7 million people worldwide. Traditional high frequency, isochronal deep brain stimulation (DBS) is an effective treatment for the motor signs associated with PD. Clinical outcomes, however, vary across centers and within centers across patients. Adverse effects can be induced by “current-spread” to unintended brain areas when the DBS lead is sub-optimally placed which limits clinical benefits. Coordinated reset (CR) DBS is a promising novel DBS approach that has the potential to overcome the limitations of traditional DBS. By alternating lower intensity stimulation delivered in a burst pattern across different contacts of the DBS lead, CR DBS is associated with less current spread, thus reducing the incidence of adverse effects, and improvement in motor signs that persist for days to weeks after cessation of stimulation, i.e. carryover effect. Although the effectiveness of CR DBS has been demonstrated in both preclinical and clinical studies, the selection of CR parameters that provide the greatest carryover effect has been challenging. The optimal target for CR DBS must also be identified. The proposed study using a within-subject experimental design will 1) optimize the critical parameter (cycle rate) of CR DBS, (2) compare the effect of CR DBS in the subthalamic nucleus (STN) and internal segment of the globus pallidus (GPi), and (3) characterize the changes in cortical and subcortical neuronal activities associated with its therapeutic effect. The nonhuman primate model of PD will be used with each animal implanted with DBS leads in the STN and GPi and high- density Utah arrays placed over the primary motor, dorsal premotor and dorsolateral prefrontal cortices. Objective and quantitative motor assessments will be performed to measure the acute and carryover effect of CR DBS with different cycle rates and in different targets (STN and GPi). The central hypothesis is that the therapeutic effect of CR DBS is greatest when the cycle rate is based on subject-specific pathophysiological biomarkers associated with the PD state. We further hypothesize that CR DBS in GPi will provide greater acute benefits in motor signs and induce significantly longer carryover effects. We predict that motor improvements induced by CR DBS will correlate with a reduction in synchronized neuronal activity within and across cortical and subcortical nodal points in the basal-ganglia-thalamocortical (BGTC) circuit. The results of this study will provide a time efficient approach for the selection of CR DBS cycle rate based on subject-specific biomarker activity in the BGTC circuit, identify the optimal target for CR DBS and enhance our understanding of the mechanism(s) underlying the therapeutic effect of CR DBS. Results of the study will significantly advance the development of CR DBS for the treatment of PD that will enhance clinical outcomes, prolong battery life and induce fewer side effects leading to higher quality of life for PD patients undergoing DBS.

项目总结/文摘